Moderna announces plans to set up subsidiary in Taiwan

preview_player
Показать описание
U.S. vaccine maker Moderna has announced an expansion into the Asia-Pacific, with four subsidiaries in the region, including one in Taiwan. In a press release, the CEO was quoted as saying that Moderna is looking forward to new opportunities to leverage the company''s mRNA platform~ to help solve health challenges in the Asia-Pacific region.

With a presence in 12 countries around the world, including Japan, South Korea, and Australia, Moderna is not only known for its COVID vaccines. In its development pipeline are 40 mRNA-based vaccines and therapeutics~ targeting areas such as rare diseases, immune-oncology, and autoimmune diseases, 25 of which are now undergoing clinical trials. Moderna is expected to deliver 35 million doses of next-generation COVID-19 vaccines to Taiwan, with 20 million in 2022 and 15 million scheduled for 2023.
Рекомендации по теме
Комментарии
Автор

Be careful of Moderna, therapeutics are always the best direction. Plus immune system strengthening neutrients, such as Mizo soup, anise (fennel seeds) & vitamin supplements.

georgeadams